Rock Springs Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Rock Springs Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-151,000	Closed	-$10.6M	–	110
2024 Q3	$10.6M	Hold	151,000	–	–	0.35%	66
2024 Q2	$12.4M	Buy	151,000 +2,168	+1%	+$180K	0.37%	65
2024 Q1	$13M	Hold	148,832	–	–	0.33%	72
2023 Q4	$14.4M	Sell	148,832 -115,668	-44%	-$10.2M	0.35%	65
2023 Q3	$23.4M	Hold	264,500	–	–	0.63%	53
2023 Q2	$22.9M	Hold	264,500	–	–	0.55%	55
2023 Q1	$25.7M	Hold	264,500	–	–	0.61%	51
2022 Q4	$27.4M	Hold	264,500	–	–	0.66%	48
2022 Q3	$22.4M	Hold	264,500	–	–	0.58%	51
2022 Q2	$21.9M	Hold	264,500	–	–	0.64%	47
2022 Q1	$20.4M	Buy	264,500 +500	+0.2%	+$41.8K	0.51%	59
2021 Q4	$23.3M	Buy	264,000 +10,500	+4%	+$866K	0.54%	59
2021 Q3	$19.6M	Hold	253,500	–	–	0.41%	74
2021 Q2	$21.2M	Hold	253,500	–	–	0.42%	72
2021 Q1	$19.1M	Hold	253,500	–	–	0.42%	74
2020 Q4	$22.2M	Sell	253,500 -96,500	-28%	-$7.65M	0.47%	74
2020 Q3	$26.6M	Sell	350,000 -37,500	-10%	-$3.79M	0.68%	47
2020 Q2	$47.8M	Buy	387,500 +7,500	+2%	+$745K	1.31%	22
2020 Q1	$32.1M	Buy	380,000 +42,500	+13%	+$3.66M	1.33%	27
2019 Q4	$28.5M	Buy	337,500 +195,000	+137%	+$14.7M	0.9%	46
2019 Q3	$9.61M	Hold	142,500	–	–	0.38%	79
2019 Q2	$12.2M	Buy	142,500 +7,500	+6%	+$642K	0.44%	77
2019 Q1	$12M	Buy	135,000 +6,000	+5%	+$556K	0.46%	73
2018 Q4	$11M	Buy	129,000 +4,000	+3%	+$381K	0.52%	64
2018 Q3	$12.1M	Hold	125,000	–	–	0.44%	74
2018 Q2	$11.8M	Hold	125,000	–	–	0.45%	76
2018 Q1	$10.1M	Hold	125,000	–	–	0.43%	78
2017 Q4	$11.1M	Hold	125,000	–	–	0.51%	69
2017 Q3	$11.6M	Hold	125,000	–	–	0.54%	62
2017 Q2	$11.4M	Hold	125,000	–	–	0.57%	58
2017 Q1	$11M	Hold	125,000	–	–	0.63%	51
2016 Q4	$10.4M	Hold	125,000	–	–	0.69%	48
2016 Q3	$11.6M	Buy	125,000 +12,000	+11%	+$1.13M	0.73%	48
2016 Q2	$8.79M	Buy	113,000 +9,750	+9%	+$829K	0.65%	48
2016 Q1	$8.52M	Buy	103,250 +33,250	+48%	+$2.71M	0.71%	43
2015 Q4	$7.33M	Buy	70,000 +19,500	+39%	+$2.04M	0.56%	63
2015 Q3	$5.32M	Buy	50,500 +18,000	+55%	+$2.4M	0.43%	76
2015 Q2	$4.45M	Hold	32,500	–	–	0.32%	96
2015 Q1	$4.05M	Buy	+32,500	New	+$3.44M	0.38%	84

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Rock Springs Capital Management's BMRN Position: Q4 2024 in Review

Rock Springs Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2024, closing a stake of 151,000 shares — an estimated $10.6M sold.

Rock Springs Capital Management first reported a position in BMRN in Q1 2015 and held it in 39 quarters. The position peaked at $47.8M in Q2 2020. 543 funds tracked by Wall St. Rank hold BMRN as of Q4 2024.

Rock Springs Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Rock Springs Capital Management sold 151,000 BioMarin Pharmaceuticals shares in Q4 2024, an estimated $10.6M.
Rock Springs Capital Management first reported a position in BioMarin Pharmaceuticals in Q1 2015 and held it in 39 quarters.
Rock Springs Capital Management's BioMarin Pharmaceuticals position peaked at $47.8M in Q2 2020.
543 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2024.

Based on Rock Springs Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.